135 related articles for article (PubMed ID: 17245477)
41. Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.
Nishio K; Shigemitsu M; Kodama Y; Konno N; Katagiri T; Kobayashi Y
Cardiovasc Revasc Med; 2009; 10(1):5-11. PubMed ID: 19159848
[TBL] [Abstract][Full Text] [Related]
42. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
[No Abstract] [Full Text] [Related]
43. The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?
Singaram V; Pratley R
Diab Vasc Dis Res; 2007 Sep; 4(3):237-40. PubMed ID: 17907116
[TBL] [Abstract][Full Text] [Related]
44. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.
Dormandy J; Bhattacharya M; van Troostenburg de Bruyn AR;
Drug Saf; 2009; 32(3):187-202. PubMed ID: 19338377
[TBL] [Abstract][Full Text] [Related]
45. [Pioglitazone. Review of its metabolic and systemic effects].
Rodríguez Bernardino A; Cebrián Blanco S; Durán García S
Rev Clin Esp; 2005 Dec; 205(12):610-20. PubMed ID: 16527183
[TBL] [Abstract][Full Text] [Related]
46. Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11).
Dormandy JA; Betteridge DJ; Schernthaner G; Pirags V; Norgren L;
Atherosclerosis; 2009 Jan; 202(1):272-81. PubMed ID: 18538774
[TBL] [Abstract][Full Text] [Related]
47. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
48. Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88].
Miranda VP; Rodrigues MJ; Gonçalves FR; Nunes JP
Rev Port Cardiol; 2009 Oct; 28(10):1099-119. PubMed ID: 20058777
[TBL] [Abstract][Full Text] [Related]
49. Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes--update 2008.
Rohatgi A; McGuire DK
Cardiovasc Drugs Ther; 2008 Jun; 22(3):233-40. PubMed ID: 18373186
[TBL] [Abstract][Full Text] [Related]
50. [41th Congress of EASD (European Association for The Study of Diabetes) 10 to 15 September 2005, Athens, Greece].
Simorre B
Rev Med Interne; 2006 Apr; 27(4):356-7. PubMed ID: 16703668
[No Abstract] [Full Text] [Related]
51. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
[TBL] [Abstract][Full Text] [Related]
52. Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis.
Lee M; Saver JL; Liao HW; Lin CH; Ovbiagele B
Stroke; 2017 Feb; 48(2):388-393. PubMed ID: 27999139
[TBL] [Abstract][Full Text] [Related]
53. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.
Schernthaner G; Currie CJ; Schernthaner GH
Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S155-61. PubMed ID: 23882041
[No Abstract] [Full Text] [Related]
54. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
55. [Glycemic control and cardiovascular benefit: what do we know today?].
Egidi G; Popert U
Dtsch Med Wochenschr; 2011 May; 136(19):1027; author reply 1027-8. PubMed ID: 21544796
[No Abstract] [Full Text] [Related]
56. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
57. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
59. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
[TBL] [Abstract][Full Text] [Related]
60. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
